Intravenous Immunoglobulin Therapy in Optic Neuritis

Completed · Phase 3

Conditions studied: Optic Neuritis

In brief

To determine whether high-dose intravenous immunoglobulin (IVIg) is more effective than placebo in restoring lost visual function (visual acuity) in optic neuritis (ON). To determine the time course of recovery following IVIg administration. If the reports of IVIg-associated clinical improvement occurring within 3 to 6 months following treatment can be confirmed, this would provide indirect evidence that IVIg may promote central nervous system (CNS) remyelination in optic neuritis and multiple sclerosis (MS).

Key facts

Study ID

NCT00000117

Run by

National Eye Institute (NEI)

Starts

1995-08-01

Expected to finish

1997-12-01

Last updated by the study team

2009-09-17

Who can join

Age: any, up to 50. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Mayo Clinic, Department of Neurology — Rochester, Minnesota, United States
• Mayo Clinic — Rochester, Minnesota, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.